GigaGen, A Subsidiary Of Grifols Presents IND-Enabling Data And Phase 1 Trial Strategy For Its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, At SITC 2023
Portfolio Pulse from Benzinga Newsdesk
GigaGen, a subsidiary of Grifols, has presented IND-enabling data and the clinical trial design for its first-in-human Phase 1 study evaluating the company's oncology candidate, GIGA-564, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The Phase 1 trial will be conducted by the National Cancer Institute and is expected to start in 2024. GIGA-564 is a differentiated anti-CTLA-4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade.
November 06, 2023 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Grifols' subsidiary GigaGen has presented promising data for its oncology drug candidate, GIGA-564, and plans to initiate a Phase 1 trial in 2024. This could potentially enhance Grifols' product portfolio and future revenues if the drug proves successful.
The news is directly related to Grifols as GigaGen is its subsidiary. The successful development and approval of GIGA-564 could potentially enhance Grifols' product portfolio and future revenues. However, the drug is still in early stages of development and there are risks associated with clinical trials and regulatory approval.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100